EZH2 and cancer: Of note, a recent study has suggested EZH2, which belongs to the polycomb repressive complex 2 (PRC2) of Pc-G, as a therapeutic target of WEE1 inhibitor combinations in triple-negative and basal-like breast cancers, because EZH2 high expression in those cancers may provide a permissive environment for unscheduled mitosis, leading to mitotic slippage, apoptosis, and gross micronuclei formation43.